Who Paid My Doc
Joshua Meyerson
Pediatrics Charlevoix, MI Medical Doctor
NPI 1851383533 CMS profile 672758
220 W Garfield Ave, Charlevoix, MI 49720
General payments
$66
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Joshua Meyerson of Charlevoix, MI is reported in the CMS Open Payments database as having received $66 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 26th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $16 | 1 | |
| 2022 | General | $50 | 1 |
Beside peers
- Joshua Meyerson
- Pediatrics median
- Middle half of Pediatrics
- National median
In program year 2025, general payments to Joshua Meyerson were reported at $0. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.
Show as a table
| Year | Joshua Meyerson | Pediatrics median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $86 | $31–$183 | $163 |
| 2020 | $0 | $49 | $22–$110 | $114 |
| 2021 | $0 | $68 | $27–$158 | $132 |
| 2022 | $50 | $77 | $30–$173 | $149 |
| 2023 | $0 | $88 | $33–$190 | $160 |
| 2024 | $16 | $94 | $34–$206 | $164 |
| 2025 | $0 | $97 | $37–$210 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
761
Drug cost
$165,007
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Abrysvo Rsv Vacc, Pref A And Pref B/Pf | Brand | 234 | $73,310 | |
| Shingrix Varicella-Zoster Ge/As01b/Pf | Brand | 188 | $41,629 | |
| Arexvy Rsvpref3 Antigen/As01e/Pf | Brand | 90 | $28,583 | |
| Havrix Hepatitis A Virus Vaccine/Pf | Brand | 99 | $9,387 | |
| Adacel Tdap Diph,pertuss(Acell),tet Vac/Pf | Brand | 59 | $4,299 | |
| Menveo A-C-Y-W-135-Dip Mening Vac A,c,y,w-135 Dip/Pf | Brand | 13 | $2,328 | |
| Boostrix Tdap Diphth,pertuss(Acell),tet Vac | Brand | 32 | $2,071 | |
| M-M-R Ii Vaccine Measles,mumps,rubella Vacc/Pf | Brand | 13 | $1,482 | |
| Ipol Poliomyelitis Vaccine, Killed | Brand | 17 | $1,066 | |
| Pedvaxhib Haemph B Polysac Conj-Menin/Pf | Brand | 16 | $852 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 12 billing codesPaid by Medicare
$27,000
Medicare patients
123
Services billed
375
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 73% | |
| Arthritis | 41% | |
| Diabetes | 21% | |
| Ischemic heart disease | 18% | |
| Atrial fibrillation | 17% | |
| Chronic kidney disease | 15% | |
| COPD | 15% | |
| Depression | 11% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Sarscov2 vac 50 mcg/0.5ml im 91322 | Office | 79 | 80 | $11,593 |
| Vaccine for influenza for injection into muscle 90653 | Office | 58 | 58 | $4,215 |
| Pcv20 vaccine im 90677 | Office | 11 | 11 | $3,204 |
| Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 | Office | 30 | 30 | $657 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
3 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| GARDASIL 9 |
|
$3 | — | — |
| VAQTA |
|
$3 | — | — |
| GARDASIL |
|
$3 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatrics in Michigan
Related records
Pediatrics in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Pediatrics
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.